Pular para o conteúdo
ORPHA:411533DOENÇA RARA
Esta doença tem causa genética. Recomendamos procurar um médico geneticista para diagnóstico, exames genéticos e aconselhamento familiar.
Visão / ocular
Também conhecida comoMelanoma maligno

Tumor maligno, geralmente agressivo, composto por melanócitos neoplásicos atípicos. Na maioria das vezes, os melanomas surgem na pele (melanomas cutâneos) e incluem os seguintes subtipos histológicos: melanoma extensivo superficial, melanoma nodular, melanoma lentiginoso acral e melanoma lentigo maligno. Os melanomas cutâneos podem surgir de nevos melanocíticos ou displásicos adquiridos ou congênitos. Os melanomas também podem surgir em outros locais anatômicos, incluindo o sistema gastrointestinal, olhos, trato urinário e sistema reprodutivo. Os melanomas freqüentemente metastatizam para os gânglios linfáticos, fígado, pulmões e cérebro.

Em construçãohistóricoSugerir correção
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

💬
EM LINGUAGEM SIMPLES

O melanoma é um tipo de câncer de pele que começa em células produtoras de pigmento chamadas melanócitos. Esse câncer geralmente ocorre em áreas que são expostas ao sol apenas ocasionalmente; os tumores são mais comumente encontrados nas costas dos homens e nas pernas das mulheres. O melanoma costuma ocorrer na pele (melanoma cutâneo), mas em cerca de 5 por cento dos casos ele se desenvolve nos melanócitos de outros tecidos, incluindo os olhos (melanoma uveal) ou as membranas mucosas que revestem as cavidades do corpo, como o revestimento úmido da boca (melanoma mucoso). O melanoma pode se desenvolver em qualquer idade, mas ocorre com mais frequência em pessoas na faixa dos cinquenta aos setenta anos e está se tornando mais comum em adolescentes e jovens adultos.

O melanoma pode se desenvolver a partir de uma pinta existente ou de outro crescimento cutâneo normal que se torna canceroso (maligno); no entanto, muitos melanomas são novos crescimentos. Os melanomas frequentemente apresentam bordas irregulares e forma irregular. Eles podem variar de alguns milímetros a vários centímetros de diâmetro. Também podem apresentar uma variedade de cores: marrom, preto, vermelho, rosa, azul ou branco.

A maioria dos melanomas afeta apenas a camada mais externa da pele (a epiderme). Se um melanoma se tornar mais espesso e envolver múltiplas camadas da pele, ele pode se espalhar para outras partes do corpo (metastatizar).

Um grande número de pintas ou outros crescimentos cutâneos pigmentados no corpo, geralmente mais de 25, está associado a um risco aumentado de desenvolver melanoma. O melanoma também é uma característica comum de síndromes genéticas que afetam a pele, como xeroderma pigmentoso. Além disso, pessoas que já tiveram melanoma têm quase nove vezes mais probabilidade de desenvolver melanoma novamente em comparação com a população geral. Estima-se que cerca de 90 por cento das pessoas com melanoma sobrevivam pelo menos 5 anos após o diagnóstico.

Fonte: MedlinePlus Genetics (NLM/NIH), traduzido
📋
Informacoes curadas por IA — podem conter imprecisoes

Tumor maligno, geralmente agressivo, composto por melanócitos neoplásicos atípicos. Na maioria das vezes, os melanomas surgem na pele (melanomas cutâneos) e incluem os seguintes subtipos histológicos: melanoma extensivo superficial, melanoma nodular, melanoma lentiginoso acral e melanoma lentigo maligno. Os melanomas cutâneos podem surgir de nevos melanocíticos ou displásicos adquiridos ou congênitos. Os melanomas também podem surgir em outros locais anatômicos, incluindo o sistema gastrointestinal, olhos, trato urinário e sistema reprodutivo. Os melanomas freqüentemente metastatizam para os gânglios linfáticos, fígado, pulmões e cérebro.

Pesquisas ativas
815 ensaios
3557 total registrados no ClinicalTrials.gov
Publicações científicas
154.059 artigos
Último publicado: 2026 Apr 17
Medicamentos
4 com registro
DACARBAZINA, EVODAZIN, FAULDACAR

Tem tratamento?

✓ 4 medicamentos específicos desta doença (registro ANVISA, FDA ou SUS/CEAF)
Ver detalhes, fases e interações →
DACARBAZINAEVODAZINFAULDACARDACARB
🏥
SUS: Cobertura mínimaScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

👁️
Olhos
7 sintomas
🧬
Pele e cabelo
3 sintomas
🩸
Sangue
1 sintomas
🫃
Digestivo
1 sintomas

+ 17 sintomas em outras categorias

Características mais comuns

—
Melanoma uveal
—
Perda visual
—
Melanoma
—
Neoplasia do estômago
—
Neoplasia da mama
—
Melanoma coroide
29sintomas
Sem dados (29)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 29 características clínicas mais associadas, ordenadas por frequência.

Melanoma uvealUveal melanoma
Perda visualVisual loss
Neoplasia do estômagoNeoplasm of the stomach
Neoplasia da mamaNeoplasm of the breast

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa11
Total histórico154.059PubMed
Últimos 10 anos96publicações
Pico202013 papers
Linha do tempo
20202015Hoje · 2026🧪 1971Primeiro ensaio clínico📈 2020Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

15 genes identificados com associação a esta condição.

CDK4Cyclin-dependent kinase 4Candidate gene tested inRestrito
VIAS BIOLÓGICAS (7)
Cyclin D associated events in G1Transcriptional regulation by RUNX2Ubiquitin-dependent degradation of Cyclin DMeiotic recombinationRMTs methylate histone arginines
MECANISMO DE DOENÇA

Melanoma, cutaneous malignant 3

A malignant neoplasm of melanocytes, arising de novo or from a pre-existing benign nevus, which occurs most often in the skin but may also involve other sites.

OUTRAS DOENÇAS (4)
familial melanomadedifferentiated liposarcomawell-differentiated liposarcomamelanoma, cutaneous malignant, susceptibility to, 3
HGNC:1773UniProt:P11802
GNA11Guanine nucleotide-binding protein subunit alpha-11Candidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (10)
PLC beta mediated eventsG-protein activationADP signalling through P2Y purinoceptor 1G alpha (q) signalling eventsThrombin signalling through proteinase activated receptors (PARs)
MECANISMO DE DOENÇA

Hypocalciuric hypercalcemia, familial 2

A form of hypocalciuric hypercalcemia, a disorder of mineral homeostasis that is transmitted as an autosomal dominant trait with a high degree of penetrance. It is characterized biochemically by lifelong elevation of serum calcium concentrations and is associated with inappropriately low urinary calcium excretion and a normal or mildly elevated circulating parathyroid hormone level. Hypermagnesemia is typically present. Affected individuals are usually asymptomatic and the disorder is considered benign. However, chondrocalcinosis and pancreatitis occur in some adults.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
153.0 TPM
Cérebro - Hemisfério cerebelar
140.5 TPM
Testículo
104.7 TPM
Esôfago - Muscular
97.3 TPM
Fallopian Tube
94.3 TPM
OUTRAS DOENÇAS (8)
autosomal dominant hypocalcemia 2familial hypocalciuric hypercalcemia 2anastomosing haemangiomauveal melanoma
HGNC:4379UniProt:P29992
GNAQGuanine nucleotide-binding protein G(q) subunit alphaCandidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (10)
PLC beta mediated eventsG-protein activationADP signalling through P2Y purinoceptor 1G alpha (q) signalling eventsThrombin signalling through proteinase activated receptors (PARs)
MECANISMO DE DOENÇA

Capillary malformations, congenital

A form of vascular malformations that are present from birth, tend to grow with the individual, do not regress spontaneously, and show normal rates of endothelial cell turnover. Capillary malformations are distinct from capillary hemangiomas, which are highly proliferative lesions that appear shortly after birth and show rapid growth, slow involution, and endothelial hypercellularity.

EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
54.7 TPM
Brain Frontal Cortex BA9
54.1 TPM
Brain Spinal cord cervical c-1
53.3 TPM
Pulmão
51.6 TPM
Aorta
48.3 TPM
OUTRAS DOENÇAS (5)
Sturge-Weber syndromefamilial multiple nevi flammeianastomosing haemangiomauveal melanoma
HGNC:4390UniProt:P50148
CDKN2ACyclin-dependent kinase inhibitor 2ACandidate gene tested inRestrito
VIAS BIOLÓGICAS (8)
Regulation of TP53 DegradationOncogene Induced SenescenceOxidative Stress Induced SenescenceStabilization of p53Regulation of RUNX3 expression and activity
OUTRAS DOENÇAS (10)
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)familial melanomaLi-Fraumeni syndromefamilial atypical multiple mole melanoma syndrome
HGNC:1787UniProt:P42771
POT1Protection of telomeres protein 1Candidate gene tested inTolerante
VIAS BIOLÓGICAS (10)
DNA Damage/Telomere Stress Induced SenescencePackaging Of Telomere EndsMeiotic synapsisInhibition of DNA recombination at telomereTelomere C-strand (Lagging Strand) Synthesis
MECANISMO DE DOENÇA

Tumor predisposition syndrome 3

An autosomal dominant disorder characterized by an increased risk for the development of various types of benign and malignant neoplasms throughout life, with age-dependent penetrance. Affected individuals can develop neoplasms involving epithelial, mesenchymal, and neuronal tissues, as well as lymphoid and myeloid cancers. The disorder is associated with elongated telomeres.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
22.7 TPM
Nervo tibial
15.9 TPM
Testículo
15.3 TPM
Cervix Ectocervix
13.7 TPM
Útero
13.5 TPM
OUTRAS DOENÇAS (7)
tumor predisposition syndrome 3pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 8cerebroretinal microangiopathy with calcifications and cysts 3oligodendroglioma
HGNC:17284UniProt:Q9NUX5
CDKN2BCyclin-dependent kinase 4 inhibitor BCandidate gene tested inTolerante
VIAS BIOLÓGICAS (5)
Cyclin D associated events in G1Senescence-Associated Secretory Phenotype (SASP)Oncogene Induced SenescenceOxidative Stress Induced SenescenceSMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
OUTRAS DOENÇAS (2)
familial melanomamultiple endocrine neoplasia type 1
HGNC:1788UniProt:P42772
SF3B1Splicing factor 3B subunit 1Candidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (5)
Dengue Virus-Host InteractionsmRNA Splicing - Major PathwaymRNA PolyadenylationmRNA Splicing - Minor PathwayB-WICH complex positively regulates rRNA expression
EXPRESSÃO TECIDUAL(Ubíquo)
Cervix Endocervix
245.2 TPM
Útero
235.8 TPM
Ovário
231.2 TPM
Cervix Ectocervix
226.6 TPM
Baço
211.5 TPM
OUTRAS DOENÇAS (3)
myelodysplastic syndromeuveal melanomamyelodysplastic syndrome with ring sideroblasts
HGNC:10768UniProt:O75533
MITFMicrophthalmia-associated transcription factorCandidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (2)
Transcriptional and post-translational regulation of MITF-M expression and activitySUMOylation of transcription factors
MECANISMO DE DOENÇA

Waardenburg syndrome 2A

WS2 is a genetically heterogeneous, autosomal dominant disorder characterized by sensorineural deafness, pigmentary disturbances, and absence of dystopia canthorum. The frequency of deafness is higher in WS2 than in WS1.

EXPRESSÃO TECIDUAL(Ubíquo)
Cervix Ectocervix
70.8 TPM
Cervix Endocervix
58.0 TPM
Útero
57.6 TPM
Músculo esquelético
25.9 TPM
Esôfago - Muscular
24.4 TPM
OUTRAS DOENÇAS (9)
Waardenburg syndrome type 2ATietz syndromecoloboma, osteopetrosis, microphthalmia, macrocephaly, albinism, and deafnesspapillary renal cell carcinoma
HGNC:7105UniProt:O75030
MGMTMethylated-DNA--protein-cysteine methyltransferaseCandidate gene tested inTolerante
VIAS BIOLÓGICAS (1)
MGMT-mediated DNA damage reversal
EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
38.0 TPM
Testículo
25.7 TPM
Tecido adiposo
25.1 TPM
Mama
24.2 TPM
Bladder
23.6 TPM
OUTRAS DOENÇAS (3)
gliosarcomafamilial melanomagiant cell glioblastoma
HGNC:7059UniProt:P16455
TERF2IPTelomeric repeat-binding factor 2-interacting protein 1Candidate gene tested inTolerante
VIAS BIOLÓGICAS (10)
DNA Damage/Telomere Stress Induced SenescencePackaging Of Telomere EndsMeiotic synapsisInhibition of DNA recombination at telomereTelomere C-strand (Lagging Strand) Synthesis
EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
302.5 TPM
Cerebelo
219.2 TPM
Brain Frontal Cortex BA9
186.8 TPM
Pituitária
180.2 TPM
Hipotálamo
156.5 TPM
OUTRAS DOENÇAS (1)
familial melanoma
HGNC:19246UniProt:Q9NYB0
TERTTelomerase reverse transcriptaseCandidate gene tested inRestrito
VIAS BIOLÓGICAS (3)
Telomere Extension By TelomeraseFormation of the beta-catenin:TCF transactivating complexRegulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence
EXPRESSÃO TECIDUAL(Baixa expressão)
Testículo
2.7 TPM
Intestino delgado
0.7 TPM
Brain Caudate basal ganglia
0.6 TPM
Cólon transverso
0.5 TPM
Brain Nucleus accumbens basal ganglia
0.5 TPM
OUTRAS DOENÇAS (13)
dyskeratosis congenita, autosomal dominant 2pulmonary fibrosis and/or bone marrow failure, Telomere-related, 1adrenal cortex carcinomaclear cell sarcoma of kidney
HGNC:11730UniProt:O14746
BAP1Ubiquitin carboxyl-terminal hydrolase BAP1Candidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (2)
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaksUCH proteinases
OUTRAS DOENÇAS (8)
Kury-Isidor syndromeBAP1-related tumor predisposition syndromecomplex neurodevelopmental disordermeningioma
HGNC:950UniProt:Q92560
CYSLTR2Cysteinyl leukotriene receptor 2Candidate gene tested inDesconhecido
VIAS BIOLÓGICAS (4)
G alpha (q) signalling eventsLeukotriene receptorsLTC4-CYSLTR mediated IL4 productionG alpha (s) signalling events
EXPRESSÃO TECIDUAL(Tecido-específico)
Glândula adrenal
7.5 TPM
Coração - Átrio
4.8 TPM
Baço
3.1 TPM
Coração - Ventrículo esquerdo
2.8 TPM
Brain Anterior cingulate cortex BA24
1.9 TPM
OUTRAS DOENÇAS (1)
uveal melanoma
HGNC:18274UniProt:Q9NS75
MC1RMelanocyte-stimulating hormone receptorCandidate gene tested inDesconhecido
VIAS BIOLÓGICAS (3)
G alpha (s) signalling eventsPeptide ligand-binding receptorsTranscriptional and post-translational regulation of MITF-M expression and activity
MECANISMO DE DOENÇA

Melanoma, cutaneous malignant 5

A malignant neoplasm of melanocytes, arising de novo or from a pre-existing benign nevus, which occurs most often in the skin but may also involve other sites.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
53.9 TPM
Pituitária
34.8 TPM
Cerebelo
32.6 TPM
Cérebro - Hemisfério cerebelar
29.1 TPM
Tireoide
26.9 TPM
OUTRAS DOENÇAS (4)
obsolete skin/hair/eye pigmentation, variation in, 2familial melanomaoculocutaneous albinism type 2melanoma, cutaneous malignant, susceptibility to, 5
HGNC:6929UniProt:Q01726
ACDAdrenocortical dysplasia protein homologCandidate gene tested inTolerante
VIAS BIOLÓGICAS (10)
DNA Damage/Telomere Stress Induced SenescencePackaging Of Telomere EndsMeiotic synapsisInhibition of DNA recombination at telomereTelomere C-strand (Lagging Strand) Synthesis
MECANISMO DE DOENÇA

Dyskeratosis congenita, autosomal dominant, 6

A form of dyskeratosis congenita, a rare multisystem disorder caused by defective telomere maintenance. It is characterized by progressive bone marrow failure, and the clinical triad of reticulated skin hyperpigmentation, nail dystrophy, and mucosal leukoplakia. Common but variable features include premature graying, aplastic anemia, low platelets, osteoporosis, pulmonary fibrosis, and liver fibrosis among others. Early mortality is often associated with bone marrow failure, infections, fatal pulmonary complications, or malignancy.

OUTRAS DOENÇAS (4)
dyskeratosis congenita, autosomal dominant 6inherited aplastic anemiafamilial melanomaHoyeraal-Hreidarsson syndrome
HGNC:25070UniProt:Q96AP0

Variantes genéticas (ClinVar)

182 variantes patogênicas registradas no ClinVar.

🧬 ACD: NM_001082486.2(ACD):c.742G>C (p.Gly248Arg) ()
🧬 ACD: GRCh37/hg19 16q22.1(chr16:67538639-69583342)x1 ()
🧬 ACD: NM_001082486.2(ACD):c.89_92dup (p.Leu32fs) ()
🧬 ACD: GRCh37/hg19 16q22.1(chr16:67322830-69368947)x1 ()
🧬 ACD: NM_001082486.2(ACD):c.-37C>G ()
Ver todas no ClinVar

Vias biológicas (Reactome)

69 vias biológicas associadas aos genes desta condição.

SCF(Skp2)-mediated degradation of p27/p21 Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence RMTs methylate histone arginines Transcriptional regulation of white adipocyte differentiation Cyclin D associated events in G1 Ubiquitin-dependent degradation of Cyclin D PTK6 Regulates Cell Cycle Transcriptional regulation by RUNX2 Meiotic recombination Transcriptional regulation of granulopoiesis Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) Drug-mediated inhibition of CDK4/CDK6 activity SPOP-mediated proteasomal degradation of PD-L1(CD274) PLC beta mediated events G-protein activation Acetylcholine regulates insulin secretion G alpha (q) signalling events ADP signalling through P2Y purinoceptor 1 Thromboxane signalling through TP receptor Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion Thrombin signalling through proteinase activated receptors (PARs) Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells Transcriptional Regulation by VENTX Regulation of MITF-M-dependent genes involved in cell cycle and proliferation Recognition and association of DNA glycosylase with site containing an affected pyrimidine Cleavage of the damaged pyrimidine Recognition and association of DNA glycosylase with site containing an affected purine Cleavage of the damaged purine Meiotic synapsis Packaging Of Telomere Ends Telomere Extension By Telomerase Polymerase switching on the C-strand of the telomere Processive synthesis on the C-strand of the telomere Telomere C-strand (Lagging Strand) Synthesis Telomere C-strand synthesis initiation Removal of the Flap Intermediate from the C-strand DNA Damage/Telomere Stress Induced Senescence Inhibition of DNA recombination at telomere SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription B-WICH complex positively regulates rRNA expression mRNA Splicing - Major Pathway mRNA Splicing - Minor Pathway mRNA Polyadenylation Dengue Virus-Host Interactions SUMOylation of transcription factors Regulation of MITF-M-dependent genes involved in pigmentation Regulation of MITF-M-dependent genes involved in apoptosis Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence Regulation of MITF-M dependent genes involved in metabolism Regulation of MITF-M dependent genes involved in invasion Transcriptional and post-translational regulation of MITF-M expression and activity Regulation of MITF-M-dependent genes involved in lysosome biogenesis and autophagy Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition MGMT-mediated DNA damage reversal Formation of the beta-catenin:TCF transactivating complex UCH proteinases Epigenetic regulation of gene expression by MLL3 and MLL4 complexes Leukotriene receptors G alpha (s) signalling events LTC4-CYSLTR mediated IL4 production Peptide ligand-binding receptors

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
✓Aprovado1
3Fase 37
2Fase 242
1Fase 118
·Pré-clínico32
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 100 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Melanoma

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Onde estão os ensaios

Com ensaio aberto em 50 países. O ponto verde marca onde há vaga agora.

🟢 Recrutando agora

100 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

NCT07476326 · Pharmacokinetics, Safety, and Immunogenicity Comparison of B…Recrutando
PHASE1🇧🇷 Brasil · 🇨🇱 Chile · Georgia +7
NCT07581509 · Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and…Recrutando
PHASE1🇧🇷 Brasil
NCT07680699 · NEOSENT: Early Anti-PD-1 Therapy In High-Risk Stage II Melan…Recrutando
🇧🇷 Brasil
NCT06112314 · IMC-F106C Regimen Versus Nivolumab Regimens in Previously Un…Recrutando
PHASE3🇧🇷 Brasil · 🇦🇷 Argentina · 🇦🇺 Austrália +23
NCT06330064 · A Study to Evaluate the Efficacy and Safety of Ifinatamab De…Recrutando
PHASE1, PHASE2🇧🇷 Brasil · 🇦🇷 Argentina · 🇦🇺 Austrália +15
NCT02332668 · A Study of Pembrolizumab (MK-3475) in Pediatric Participants…Recrutando
PHASE1, PHASE2🇧🇷 Brasil · 🇫🇷 França · 🇩🇪 Alemanha +7
NCT07621614 · A Study on How to Safely Guide Surgery for Melanoma and Simi…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT07704918 · Aggressive Lipid Lowering Therapy in ICI-Treated MelanomaRecrutando
NA🇺🇸 Estados Unidos
NCT07661966 · Bright Light Therapy in Patients With Melanoma or Non-small …Recrutando
NA🇺🇸 Estados Unidos
NCT07847359 · Cryoablation Combined With Hepatic Arterial Infusion of Ipar…Recrutando
PHASE2🇨🇳 China
NCT06365619 · Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT07281924 · Hepzato Kit and Opdualag for Metastatic Melanoma and Liver M…Recrutando
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT07830225 · A Pilot Study of ctDNA-Guided Immune Checkpoint Inhibitor Du…Recrutando
NA🇺🇸 Estados Unidos
NCT07804186 · Study of Adjuvant Darovasertib and Crizotinib in Participant…Recrutando
PHASE3🇨🇦 Canadá · 🇺🇸 Estados Unidos
NCT07718243 · Investigating the Combination of Bexmarilimab and Nivolumab …Recrutando
PHASE1, PHASE2🇬🇧 Reino Unido
NCT06319196 · Clear Me: Interception Trial to Detect and Clear Molecular R…Recrutando
PHASE2🇨🇦 Canadá
NCT07691255 · MELanoma Brain Metastasis Treated With CYberknifeRecrutando
🇮🇹 Itália
NCT07341737 · SL-28 for Advanced Solid TumoursRecrutando
PHASE1, PHASE2🇦🇺 Austrália
NCT07696715 · Timing of Immunotherapy in MelanomaRecrutando
NA🇳🇱 Países Baixos
NCT07475572 · Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB Wit…Recrutando
PHASE1Ukraine
NCT07740941 · NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) Me…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT07686835 · Dietary Fiber to Induce Gut Microbiota-mediated Response to …Recrutando
PHASE2🇳🇱 Países Baixos
NCT07749586 · A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in…Recrutando
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT07680452 · Clinical Study on High-fiber Diet and Short-term Fasting in …Recrutando
NA🇩🇪 Alemanha
NCT07492680 · A Study of BMS-986504 Monotherapy and in Combination With Ot…Recrutando
PHASE2🇧🇪 Bélgica · 🇨🇦 Canadá · 🇨🇳 China +10
NCT07760012 · 68Ga-SorB PET/CT Imaging in Patients With Solid TumorsRecrutando
NA🇨🇳 China
NCT07649681 · Gustabor Phase 2 - Treating Taste Changes During Cancer Ther…Recrutando
NA🇩🇪 Alemanha
NCT07636785 · A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma…Recrutando
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT07518043 · A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumo…Recrutando
PHASE1🇨🇳 China
NCT07600476 · A First-in-Human Study to Evaluate the Safety, Pharmacokinet…Recrutando
PHASE1🇩🇪 Alemanha
NCT07565285 · The Efficacy and Safety of PRTX007-003 Combined With Pembrol…Recrutando
PHASE2🇦🇺 Austrália
NCT07751042 · Phase 1/2 Study of Intravenous Injection of STX-003 in Advan…Recrutando
PHASE1, PHASE2🇦🇺 Austrália · 🇺🇸 Estados Unidos
NCT07501117 · Neoadjuvant Immunotherapy for Patients With High-risk Eye Me…Recrutando
PHASE1🇩🇰 Dinamarca
NCT06971848 · Evaluation of Skin Tests in Biotherapy AllergiesRecrutando
NA🇫🇷 França
NCT07280715 · Investigating Real-Time Immunotherapy Symptoms StudyRecrutando
NA🇺🇸 Estados Unidos
NCT07339176 · Intratumoral N17350 in Advanced Solid TumorsRecrutando
PHASE1, PHASE2🇦🇺 Austrália · 🇺🇸 Estados Unidos
NCT07634380 · Sitagliptin With Pembro in RCC and MelanomaRecrutando
PHASE1🇺🇸 Estados Unidos
NCT07628634 · Feasibility Study on the Effect of a Methionine-Reduced Diet…Recrutando
EARLY_PHASE1🇺🇸 Estados Unidos
NCT07562841 · Au-TMP and Radiotherapy for Advanced Melanoma With Anti-PD-1…Recrutando
PHASE1🇨🇳 China
NCT07788729 · Social Prescriptions and Micro-Learning to Improve Care for …Recrutando
NA🇩🇪 Alemanha
NCT07068074 · Comparing the Effectiveness of Less Invasive Procedures With…Recrutando
PHASE3🇺🇸 Estados Unidos
NCT07504796 · ctDNA-guided Addition of Ipilimumab to Patients Receiving Ni…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT07400302 · Sintilimab Combined With Chemotherapy for Adjuvant Treatment…Recrutando
PHASE2🇨🇳 China
NCT07519655 · Phase 1 Study of PF-08046033 in Advanced Solid TumorsRecrutando
PHASE1🇫🇷 França · Puerto Rico · South Korea +2
NCT07288112 · DOC1021 Dendritic Cell Immunotherapy for Refractory MelanomaRecrutando
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT07552467 · Sub-topic Four: Clinical Translation of Original Radioactive…Recrutando
🇨🇳 China
NCT07750067 · Tunlametinib in Combination With Pucotenlimab and Hydroxychl…Recrutando
PHASE2🇨🇳 China
NCT07524114 · Study of High-Precision Evaluation of Molecular ResiduaL Dis…Recrutando
🇨🇦 Canadá
NCT06889610 · A Phase II Clinical Study of Multimodal Ablation Combined Wi…Recrutando
PHASE2🇨🇳 China
NCT07808164 · ENPP1/cGAS (EG) and FAP Expression Profiles in Solid Tumors:…Recrutando
Vietnam
NCT07406087 · Navigation Intervention for Adolescent and Young Adult Cance…Recrutando
NA🇺🇸 Estados Unidos
NCT07237594 · IL-17 Blockade to Decrease irAEs (REPLAY)Recrutando
PHASE1🇺🇸 Estados Unidos
NCT07584226 · A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant S…Recrutando
PHASE1🇺🇸 Estados Unidos
NCT07177937 · A Study of DXC014 in Patients With Advanced Solid Tumors.Recrutando
PHASE1🇨🇳 China
NCT07627698 · Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced MelanomaRecrutando
PHASE1, PHASE2🇨🇳 China
NCT07224425 · A Study of BI 3810944 in Patients With Advanced CancerRecrutando
PHASE1🇧🇪 Bélgica · 🇳🇱 Países Baixos · 🇺🇸 Estados Unidos
NCT07040280 · Sulforaphane for the Prevention of Melanoma in Patients With…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT07449754 · Belvarafenib in Combination With Cobimetinib in Patients Wit…Recrutando
PHASE2South Korea
NCT06999980 · Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Ev…Recrutando
PHASE2🇦🇺 Austrália
NCT07215988 · Studying Off Label Insurance Coverage for Patients With Cuta…Recrutando
🇺🇸 Estados Unidos
NCT07410676 · EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembroliz…Recrutando
PHASE1, PHASE2🇨🇳 China
NCT07354152 · COmparison of the Use of a PERforator Flap Versus Total Skin…Recrutando
🇫🇷 França
NCT07349940 · Early Detection of Skin Tumors Using a Telemedicine Tool in …Recrutando
NA🇨🇿 Tchéquia
NCT07410494 · Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR…Recrutando
PHASE1, PHASE2🇨🇳 China
NCT07848243 · Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targete…Recrutando
PHASE2🇨🇳 China
NCT07203391 · Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-c…Recrutando
PHASE1🇦🇺 Austrália
NCT07445022 · RWS of Tunlametinib in NRAS-Mutant Advanced MelanomaRecrutando
PHASE4🇨🇳 China
NCT07364474 · Immune Response to Percutaneous Hepatic Perfusion With Melph…Recrutando
NA🇺🇸 Estados Unidos
NCT07287917 · Study of AMXT 1501 and DFMO in Combination With Standard The…Recrutando
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT07015190 · Neoadjuvant Darovasertib in Primary Uveal MelanomaRecrutando
PHASE3🇦🇺 Austrália · 🇦🇹 Áustria · 🇧🇪 Bélgica +18
NCT07349303 · Neoadjuvant Pembrolizumab in Patients With Stage IIb/c Melan…Recrutando
PHASE2🇸🇪 Suécia
NCT07230613 · Neo-adjuvant Immunotherapy in Patients With Localized Melano…Recrutando
PHASE2🇫🇷 França
NCT07161310 · Urolithin A in Patients With Previously Untreated Solid Tumo…Recrutando
NA🇩🇪 Alemanha
NCT07276386 · Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp i…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT07221734 · Study to Compare Pharmacokinetics, Efficacy, Safety, and Imm…Recrutando
PHASE3🇵🇹 Portugal · Ukraine
NCT06956690 · A Phase 1/2 Clinical Trial to Assess the Safety, Tolerabilit…Recrutando
PHASE1, PHASE2🇦🇺 Austrália · 🇺🇸 Estados Unidos
NCT07280832 · Phase I/II Clinical Study of JMT108 Injection for the Treatm…Recrutando
PHASE1, PHASE2🇨🇳 China
NCT07310784 · A Phase II Trial of LM103 in Advanced MelanomaRecrutando
PHASE2🇨🇳 China
NCT07225036 · Promoting Immunotherapy Efficacy With Low-Dose Liver RTRecrutando
NA🇺🇸 Estados Unidos
NCT06887348 · A Study to Assess the Long-term Safety Outcomes in Patients …Recrutando
🇦🇺 Austrália · 🇺🇸 Estados Unidos
NCT07379138 · Studying Quality of Life Inclusive of Mental Health and Cogn…Recrutando
NA🇺🇸 Estados Unidos
NCT07042243 · The Florida ASCENT StudyRecrutando
NA🇺🇸 Estados Unidos
NCT07371663 · An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy…Recrutando
PHASE1, PHASE2🇨🇳 China
NCT06961357 · Clinical Trial of CD40L-augmented TIL for Patients With Adva…Recrutando
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT06994208 · Characteristics of Adult Patients With Melanoma Diagnosis <4…Recrutando
🇮🇹 Itália
NCT07317505 · A Phase 1 Study of JMT108 in Participants With Advanced Soli…Recrutando
PHASE1🇺🇸 Estados Unidos
NCT05770544 · DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paed…Recrutando
PHASE2, PHASE3🇬🇧 Reino Unido
NCT07136181 · Evaluation of the Safety, Efficacy, and Pharmacokinetics of …Recrutando
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT07223411 · Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunol…Recrutando
🇺🇸 Estados Unidos
NCT07266142 · Prospective Collection of Clinical Data and Human Body Mater…Recrutando
🇧🇪 Bélgica
NCT07201376 · Assessment of Skin Lesions Using a Tissue Oxygen Imager Base…Recrutando
🇺🇸 Estados Unidos
NCT07564570 · Physical Activity Directly Before Immunotherapy (Nivolumab a…Recrutando
NA🇩🇪 Alemanha
NCT07530887 · NO Re-excision MelanomA - NORMA 2Recrutando
PHASE3🇳🇱 Países Baixos
NCT07244835 · A Study of DEG6498 in Participants With Solid TumorsRecrutando
PHASE1🇨🇳 China
NCT07421739 · Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) i…Recrutando
🇦🇺 Austrália
NCT06066138 · A Study of Therapeutic Drug Monitoring-Based Atezolizumab Do…Recrutando
PHASE1🇺🇸 Estados Unidos
NCT07223424 · Patient Preference for Subcutaneous vs. Intravenous Immune T…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT07155317 · Time-of-Day Specified Immunotherapy for Advanced Melanoma, T…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT06626516 · Tebentafusp-tebn With LDT in Metastatic UMRecrutando
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT07148245 · Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous…Recrutando
🇺🇸 Estados Unidos

Outros ensaios clínicos

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

📖Melhor nível de evidência: Revisão
Timeline de publicações
72.330 papers (10 anos)

Mostrando amostra de 96 publicações de um total de 72.330

#1

Insights into RAS-driven melanoma and its therapeutic implications.

Cancer treatment reviews2026 Feb

O melanoma com mutações no gene NRAS, que afeta 15-25% dos casos cutâneos, é atualmente tratado principalmente com imunoterapia anti-PD-1, já que os inibidores de MEK demonstraram benefício clínico limitado. Contudo, há um futuro promissor com diversas novas terapias em desenvolvimento, incluindo combinações de drogas, inibidores diretos de RAS e até vacinas específicas para as mutações. Para médicos e pacientes, é crucial que o tratamento seja cada vez mais personalizado e guiado por biomarcadores para otimizar os resultados e a gestão desta doença.

🇧🇷 traduzido
#2

Intraepithelial Penile Lesions.

Advances in anatomic pathology2026 Mar 01

Este artigo descreve lesões intraepiteliais penianas, que incluem desde condições não-neoplásicas como condilomas (geralmente associados ao HPV) até lesões pré-neoplásicas, como a Neoplasia Intraepitelial Peniana (PeIN). A PeIN é crucial para médicos e pacientes devido ao seu potencial de progressão para câncer, sendo na Europa frequentemente associada ao HPV ou, em outros casos, a fatores como inflamações crônicas; e, embora raros, melanomas in situ primários do pênis também são descritos.

🇧🇷 traduzido
#3

Global burden of lower respiratory infections and aetiologies, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.

The Lancet. Infectious diseases2025 Dec 15

As infecções respiratórias inferiores (IRIs) continuam sendo a principal causa infecciosa de morte global, afetando desproporcionalmente crianças menores de 5 anos e adultos com mais de 70. O *Streptococcus pneumoniae* é o patógeno mais letal, mas o estudo também aponta para a importância crescente de micobactérias não tuberculosas e *Aspergillus spp*. Para médicos e pacientes, é crucial que o acesso equitativo a vacinas (incluindo novas para vírus sincicial respiratório), diagnóstico precoce e tratamentos eficazes seja ampliado, especialmente em regiões de alta mortalidade como a África Subsaariana, para sustentar os avanços na saúde infantil e abordar a vulnerabilidade crescente em idosos.

🇧🇷 traduzido
#4

Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023.

Lancet (London, England)2025 Nov 22

A Doença Renal Crônica (DRC) é um grave e crescente problema de saúde global, afetando 788 milhões de adultos em 2023, sendo a nona principal causa de morte e a 12ª de incapacidade mundial. Para pacientes e médicos, é crucial saber que a DRC eleva significativamente o risco de mortes cardiovasculares e está fortemente ligada a fatores controláveis como glicose alta no sangue, obesidade e pressão arterial elevada. Isso sublinha a necessidade urgente de melhor rastreamento, prevenção e controle desses fatores para mitigar a progressão da doença e melhorar os resultados dos pacientes.

🇧🇷 traduzido
#5

Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.

Lancet (London, England)2025 Oct 18

Este estudo, o Global Burden of Disease Study 2023 (GBD 2023), oferece uma análise abrangente das causas de morte global entre 1990 e 2023, revelando que a idade média de morte aumentou significativamente. Apesar do impacto temporário da COVID-19 nas classificações, doenças cardíacas e AVC continuam sendo as principais causas, enquanto houve progresso em reduzir algumas infecciosas e um aumento das doenças não-transmissíveis (DNTs) em regiões de baixa renda. Para pacientes e profissionais de saúde, este estudo sublinha a necessidade de sistemas de saúde robustos e intervenções focadas para reduzir a mortalidade prematura e as grandes disparidades globais, embora o resumo fornecido não detalhe dados específicos sobre melanoma.

🇧🇷 traduzido

Publicações recentes

Ver todas no PubMed

📚 EuropePMCmostrando 96

2026

Insights into RAS-driven melanoma and its therapeutic implications.

Cancer treatment reviews
2026

Intraepithelial Penile Lesions.

Advances in anatomic pathology
2025

Global burden of lower respiratory infections and aetiologies, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.

The Lancet. Infectious diseases
2025

Identification of a novel PRUNE2::NTRK2 gene fusion in soft tissue sarcoma patients-friend or foe? Case series.

Therapeutic advances in medical oncology
2025

Radiotherapy of sinonasal cancers: 2025 update.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
2025

Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023.

Lancet (London, England)
2025

Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.

Lancet (London, England)
2025

Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.

Lancet (London, England)
2025

Consider the unexpected! An overlooked, elusive, rare but dramatic diagnosis: anorectal melanoma.

Updates in surgery
2025

Association between ovarian sex cord-stromal tumors and non-hormone-sensitive cancers: A nationwide nested cohort study.

Journal of gynecology obstetrics and human reproduction
2025

Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study.

European journal of cancer (Oxford, England : 1990)
2025

Risk of cancer in patients with rheumatoid arthritis under tocilizumab: Data from the French national registry REGATE.

Joint bone spine
2025

Real-World Evidence of the Prevalence of Driver Mutations in Anorectal Melanoma.

Molecular diagnosis &amp; therapy
2025

Novel Variants in Medium and Low Penetrance Predisposing Genes in a Hungarian Malignant Melanoma Cohort With Increased Risk.

Pigment cell &amp; melanoma research
2024

Diagnostic trajectories of patients with rare cancer in the Netherlands: results from a nationwide cross-sectional survey.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
2025

Pathogenic Germline Variants in Uveal Melanoma Driver and BAP1-Associated Genes in Finnish Patients with Uveal Melanoma.

Pigment cell &amp; melanoma research
2024

Protein-truncating and rare missense variants in ATM and CHEK2 and associations with cancer in UK Biobank whole-exome sequence data.

Journal of medical genetics
2024

Spectrum and Frequency of BRAF Mutations in Skin Melanomas in the Dalmatian Region of Croatia.

Acta dermatovenerologica Croatica : ADC
2024

Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet (London, England)
2024

Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group.

Annals of oncology : official journal of the European Society for Medical Oncology
2023

Skin Changes in Suspected Lyme Disease.

Acta dermatovenerologica Croatica : ADC
2024

Comprehensive genomic profiling on metastatic Melanoma: results from a network screening from 7 Italian Cancer Centres.

Journal of translational medicine
2024

Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.

Nature communications
2023

Clinical practice guidelines for the diagnosis and surveillance of BAP1 tumour predisposition syndrome.

European journal of human genetics : EJHG
2023

Quality indicators: completeness, validity and timeliness of cancer registry data contributing to the European Cancer Information System.

Frontiers in oncology
2023

Genomic profiling of a metastatic anaplastic melanocytic neuroectodermal tumor arising from a mature thymic teratoma as part of a mediastinal germ cell tumor.

Cold Spring Harbor molecular case studies
2023

'Get Data Out' Skin: national cancer registry incidence and survival rates for all registered skin tumour groups for 2013-2019 in England.

The British journal of dermatology
2023

CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 study.

Cancer medicine
2022

The Transcriptional Landscape of BRAF Wild Type Metastatic Melanoma: A Pilot Study.

International journal of molecular sciences
2022

Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.

Annals of oncology : official journal of the European Society for Medical Oncology
2022

Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel.

Journal for immunotherapy of cancer
2022

Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040.

JAMA dermatology
2022

Clinical features, molecular characteristics and surgical management of primary penile mucosal melanoma based on the European Association of Urology Penile Cancer Guidelines.

Melanoma research
2022

Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology
2021

Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology
2021

Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆.

Annals of oncology : official journal of the European Society for Medical Oncology
2021

European Reference Network for rare adult solid cancers, statement and integration to health care systems of member states: a position paper of the ERN EURACAN.

ESMO open
2022

Caucasians with acral lentiginous melanoma have the same outcome as patients with stage- and limb-matched superficial spreading melanoma.

Journal of cancer research and clinical oncology
2021

Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature.

Cancer medicine
2021

Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program.

Journal of translational medicine
2020

A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors.

Therapeutic advances in medical oncology
2021

The surgical treatment of non-metastatic melanoma in a Clinical National Melanoma Registry Study Group (CNMR): a retrospective cohort quality improvement study to reduce the morbidity rates.

BMC cancer
2020

Efficacy of Electrochemotherapy in the Treatment of Cutaneous Melanoma Metastases and Rare Non-melanoma Skin Cancer.

Anticancer research
2020

Incidence and Mortality of Second Primary Cancers in Danish Patients With Retinoblastoma, 1943-2013.

JAMA network open
2020

Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial.

The Lancet. Oncology
2020

Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands - A nationwide population-based study.

European journal of cancer (Oxford, England : 1990)
2020

Ano-uro-genital mucosal melanoma UK national guidelines.

European journal of cancer (Oxford, England : 1990)
2020

Germline loss-of-function variants in MBD4 are rare in Finnish patients with uveal melanoma.

Pigment cell &amp; melanoma research
2020

Quality of treatment and surgical approach for rectal gastrointestinal stromal tumour (GIST) in a large European cohort.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
2020

Incidence and Survival of Patients With Conjunctival Melanoma in Europe.

JAMA ophthalmology
2020

Phase 2 study of pembrolizumab in patients with advanced rare cancers.

Journal for immunotherapy of cancer
2019

Incidence and mortality for cutaneous squamous cell carcinoma: comparison across three continents.

Journal of the European Academy of Dermatology and Venereology : JEADV
2020

Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network.

Cancer
2019

A novel germline variant in the DOT1L gene co-segregating in a Dutch family with a history of melanoma.

Melanoma research
2019

Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.

Melanoma research
2020

Genetic epidemiology of colorectal cancer and associated cancers.

Mutagenesis
2020

Familial aggregation of early-onset cancers.

International journal of cancer
2019

Combined analysis of keratinocyte cancers identifies novel genome-wide loci.

Human molecular genetics
2019

Comparison of quality of life between melanoma and non-melanoma skin cancer patients.

European journal of dermatology : EJD
2019

Population-based analysis of BAP1 germline variations in patients with uveal melanoma.

Human molecular genetics
2019

Defining and listing very rare cancers of paediatric age: consensus of the Joint Action on Rare Cancers in cooperation with the European Cooperative Study Group for Pediatric Rare Tumors.

European journal of cancer (Oxford, England : 1990)
2019

Risk of cancer in children and young adults conceived by assisted reproductive technology.

Human reproduction (Oxford, England)
2019

POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families.

The British journal of dermatology
2018

BRCA1/2 mutations are not a common cause of malignant melanoma in the Polish population.

PloS one
2018

Combining common genetic variants and non-genetic risk factors to predict risk of cutaneous melanoma.

Human molecular genetics
2019

Incidence and characteristics of thick second primary melanomas: a study of the German Central Malignant Melanoma Registry.

Journal of the European Academy of Dermatology and Venereology : JEADV
2018

Merkel cell carcinoma: Clinical outcome and prognostic factors in 351 patients.

Journal of surgical oncology
2018

Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.

The Lancet. Respiratory medicine
2018

Germline Variants in the POT1-Gene in High-Risk Melanoma Patients in Austria.

G3 (Bethesda, Md.)
2018

Pediatric patients with cutaneous melanoma: A European study.

Pediatric blood &amp; cancer
2018

Treatment of conjunctival melanoma in a Dutch referral centre.

The British journal of ophthalmology
2017

Clinical characteristics and outcome of 60 pediatric patients with malignant melanoma registered with the German Pediatric Rare Tumor Registry (STEP).

Klinische Padiatrie
2018

Lessons of a day hospital: Comprehensive assessment of patients with albinism in a European setting.

Pigment cell &amp; melanoma research
2017

Ultrasound-based follow-up does not increase survival in early-stage melanoma patients: A comparative cohort study.

European journal of cancer (Oxford, England : 1990)
2017

Satisfaction of mountain guides with high sun protection as a tool to prevent non-melanoma skin cancer.

Journal of the European Academy of Dermatology and Venereology : JEADV
2017

Sinonasal mucosal melanoma: A 44-case study and literature analysis.

European annals of otorhinolaryngology, head and neck diseases
2017

Do outdoor workers know their risk of NMSC? Perceptions, beliefs and preventive behaviour among farmers, roofers and gardeners.

Journal of the European Academy of Dermatology and Venereology : JEADV
2017

Prognostic role of the histological subtype of melanoma on the hands and feet in Caucasians.

Melanoma research
2017

Risk of other Cancers in Families with Melanoma: Novel Familial Links.

Scientific reports
2016

Prognostic value of two tumour staging classifications in patients with sinonasal mucosal melanoma.

European annals of otorhinolaryngology, head and neck diseases
2016

The MITF, p.E318K Variant, as a Risk Factor for Pheochromocytoma and Paraganglioma.

The Journal of clinical endocrinology and metabolism
2016

Associations between childhood height and morphologically different variants of melanoma in adulthood.

European journal of cancer (Oxford, England : 1990)
2017

Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers.

Annals of the rheumatic diseases
2016

Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile.

Acta ophthalmologica
2016

The occurrence of non-melanoma malignant skin lesions and non-cutaneous squamous-cell carcinoma among metastatic melanoma patients: an observational cohort study in Denmark.

BMC cancer
2016

Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup.

Journal of the American Academy of Dermatology
2015

A Retrospective Review of Conjunctival Melanoma Presentation, Treatment, and Outcome and an Investigation of Features Associated With BRAF Mutations.

JAMA ophthalmology
2015

Trends in survival for teenagers and young adults with cancer in the UK 1992-2006.

European journal of cancer (Oxford, England : 1990)
2015

Comparison of melanoma incidence and trends among youth under 25 years in Australia and England, 1990-2010.

International journal of cancer
2015

High nevus counts confer a favorable prognosis in melanoma patients.

International journal of cancer
2015

Molecular characterization of melanoma cases in Denmark suspected of genetic predisposition.

PloS one
2015

443 paediatric cases of malignant melanoma registered with the German Central Malignant Melanoma Registry between 1983 and 2011.

European journal of cancer (Oxford, England : 1990)
2015

The forthcoming inexorable decline of cutaneous melanoma mortality in light-skinned populations.

European journal of cancer (Oxford, England : 1990)
2015

Sinonasal malignancies in Sweden 1960-2010; a nationwide study of the Swedish population.

Rhinology
2015

Cancer-specific variation in emergency presentation by sex, age and deprivation across 27 common and rarer cancers.

British journal of cancer
2015

The MC1R melanoma risk variant p.R160W is associated with Parkinson disease.

Annals of neurology

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Melanoma.

É de uma associação que acompanha esta doença? Fale com a gente →

Doença com base genética

Um médico geneticista pode ajudar no diagnóstico de Melanoma e no aconselhamento genético da família.

Vai consultar um especialista? Confirme o registro dele no conselho.
Conselhos e sociedades

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Perguntas frequentes

O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu

Respostas geradas por IA a partir das fontes citadas

É um tumor originado a partir de melanócitos atípicos que produzem pigmento. Pode se desenvolver tanto na pele quanto em mucosas ou no globo ocular.

Referências

Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete

10 publicações do grafo RarasNet (PubMed) · 5 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.

  1. Intraepithelial Penile Lesions.
    Advances in anatomic pathology2026PMID 41568455
  2. ORPHA:411533
    Orphanet

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Citar este verbete

Raras. (s.d.). Melanoma. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/melanoma

Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Compêndio · Raras BR

Melanoma

ORPHA:411533 · MONDO:0005105
Ensaios
815 ativos
MedGen
Repurposing
9 candidatos
binimetinib — MEK inhibitor
cobimetinib — RAF inhibitor
dabrafenib — DNA alkylating agent
+6 outros
Wikipedia
Papers 10a

📋 Origem dos dados

Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.

Doença rara (ontologia)
fonte: Orphanet
Identificador unificado
fonte: MONDO
Indexação biomédica
fonte: MeSH (NLM)
Rara